Type 2 Diabetes: Clinical Trials

18 trials for Type 2 Diabetes, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 terminated. 18 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 218Terminated 18
Phase 32Terminated 2
Phase 11Terminated 1

Follow Type 2 Diabetes: new trials by email Literature Review of Type 2 Diabetes trials Research Report on Type 2 Diabetes

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
LY3549492, Placebo - Obesity, Overweight
Phase 2TerminatedEli Lilly and Company12025-06-192026-08-31
Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes
DS102, Placebo - Hypertriglyceridemia, Type 2 Diabetes
Phase 2TerminatedAfimmune2332020-10-132023-06-12
Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)
Neo-Kidney Augment - Chronic Kidney Disease, Type 2 Diabetes
Phase 2TerminatedProkidney12016-07-012021-04-23
An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus
ZGN-440 for Injectable Suspension, ZGN-440 Placebo for Injectable Suspension - Obesity, Type 2 Diabetes
Phase 2TerminatedZafgen, Inc.1522014-12-012016-01-06
Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes
ISIS-APOCIIIRX, Placebo - Type 2 Diabetes
Phase 2TerminatedIonis Pharmaceuticals, Inc.152012-07-012022-01-18
A Glomerular Filtration Rate (GFR) Measuring Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
RTA 402 - Chronic Kidney Disease, Type 2 Diabetes
Phase 2TerminatedKyowa Kirin Co., Ltd.112012-02-012017-03-03
A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
RTA 402 - Chronic Kidney Disease, Type 2 Diabetes
Phase 2TerminatedKyowa Kirin Co., Ltd.532012-02-012017-03-03
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects
EV-077, Placebo - Type 2 Diabetes
Phase 2TerminatedEvolva SA332012-01-012013-06-17
Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates
glucagon like peptide-1, glucose control - Type 2 Diabetes
Phase 1 / Phase 2TerminatedAlbert Einstein College of Medicine202010-08-122024-02-28
Hypogonadism in Young Men With Type 2 Diabetes
testosterone, clomiphene, placebo - Hypogonadotropic Hypogonadism, Type 2 Diabetes
Phase 2TerminatedState University of New York at Buffalo52010-06-012019-10-04
The Application of Extremely Low Level Magnetic Fields as Adjunctive Treatment for Type II Diabetes
Resonator device, Resonator device - sham - Type 2 Diabetes
Phase 2Terminatedpico-tesla Magnetic Therapies, LLC1652009-09-012011-05-05
Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes
INCB019602, Placebo, Metformin - Type 2 Diabetes
Phase 2TerminatedIncyte Corporation482008-05-012012-10-30
Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients
DIO-902 - Type 2 Diabetes
Phase 2 / Phase 3TerminatedDiObex1502008-01-012008-05-28
A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes
DIO-902, DIO-902 placebo - Type 2 Diabetes
Phase 2TerminatedDiObex2002007-07-012008-11-13
Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study
Fenofibrate, Metformin, Placebo - Type 2 Diabetes, Dyslipidemia
Phase 2 / Phase 3TerminatedSolvay Pharmaceuticals82006-10-012008-08-13
ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity
Tesaglitazar, Metformin, Dietary and lifestyle modification counseling - Type 2 Diabetes
Phase 2TerminatedAstraZeneca1052005-08-012008-03-17
Dose Response Study in Japanese Patients
Tesaglitazar - Type 2 Diabetes
Phase 2TerminatedAstraZeneca2502004-05-012009-04-22
Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy
nitroaspirin - Type 2 Diabetes, Early Nephropathy
Phase 2TerminatedMario Negri Institute for Pharmacological Research132003-03-012015-04-09

Narrower conditions

Diabetes Mellitus, Type 2 (18)  ·  Diabetes Mellitus (3)  ·  Renal Insufficiency, Chronic (3)  ·  Insulin Resistance (2)  ·  Obesity (2)  ·  Dyslipidemias (1)  ·  Hypertriglyceridemia (1)  ·  Hypogonadism (1)  ·  Kidney Diseases (1)  ·  Overweight (1)

Broader conditions

Endocrine System Diseases (18)  ·  Glucose Metabolism Disorders (18)  ·  Metabolic Diseases (18)  ·  Nutritional and Metabolic Diseases (18)  ·  Diabetes Mellitus (15)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Female Urogenital Diseases (4)  ·  Female Urogenital Diseases and Pregnancy Complications (4)  ·  Male Urogenital Diseases (4)  ·  Urogenital Diseases (4)  ·  Urologic Diseases (4)  ·  Chronic Disease (3)  ·  Disease Attributes (3)  ·  Kidney Diseases (3)  ·  Pathologic Processes (3)

Interventions

Metformin (3)  ·  tesaglitazar (2)  ·  CKD732 (1)  ·  Clomiphene (1)  ·  Diet (1)  ·  Fenofibrate (1)  ·  Glucagon-Like Peptide 1 (1)  ·  Glycemic Control (1)  ·  Incretins (1)  ·  Testosterone (1)  ·  epeleuton (1)  ·  nitroaspirin (1)

Sponsors

AstraZeneca (2)  ·  DiObex (2)  ·  Kyowa Kirin Co., Ltd. (2)  ·  Afimmune (1)  ·  Albert Einstein College of Medicine (1)  ·  Eli Lilly and Company (1)  ·  Evolva SA (1)  ·  Incyte Corporation (1)  ·  Ionis Pharmaceuticals, Inc. (1)  ·  Mario Negri Institute for Pharmacological Research (1)  ·  Prokidney (1)  ·  Solvay Pharmaceuticals (1)  ·  State University of New York at Buffalo (1)  ·  Zafgen, Inc. (1)  ·  pico-tesla Magnetic Therapies, LLC (1)

Countries

United States (10)  ·  Australia (3)  ·  Italy (3)  ·  Japan (3)  ·  Finland (2)  ·  Germany (2)  ·  New Zealand (2)  ·  Argentina (1)  ·  Georgia (1)  ·  Ireland (1)  ·  Israel (1)  ·  Latvia (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Ashley Johns, MSHS (1)  ·  Daniel T Stein, MD (1)  ·  Dennis Kim, MD (1)  ·  Markus Weissbach, MD (1)  ·  Piero Ruggenenti, MD (1)  ·  Sandeep Dhindsa, MBBS (1)  ·  Sherwyn Schwartz, MD (1)  ·  Thomas Jax, MD (1)  ·  William V Williams, MD (1)

Results publications

PMID 27271183, PMID 29992370

NIH funding

2005 (1), R01DK061644 (1)